MedTrace Logo

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

NCT03341806 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-01-04

No results posted yet for this study

Summary

The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.

Conditions

Interventions

DRUG

Avelumab

Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles

COMBINATION_PRODUCT

MRI-guided LITT therapy

(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT

Sponsors & Collaborators

Principal Investigators

  • Adilia Hormigo, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2021-10-13
Completion
2021-10-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341806 on ClinicalTrials.gov